Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 8Gastrointestinal 4Thoracic 3Gynecologic 3Other hematologic neoplasm 2Sarcoma 1Plasma cell 1Other solid neoplasm 1Other neoplasm 1Head & Neck 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Mouth Neoplasms 1

Interventions

Cisplatin 136Cetuximab 101pembrolizumab 83Radiotherapy 62Carboplatin 57Radiotherapy, Intensity-Modulated 54Fluorouracil 47Docetaxel 47Nivolumab 44Paclitaxel 37Radiation 21Erlotinib Hydrochloride 19durvalumab 18Platinum 15Ipilimumab 14Gemcitabine 13lenvatinib 12Drug Therapy 12Bevacizumab 12Albumin-Bound Paclitaxel 12vandetanib 11Pemetrexed 11Magnetic Resonance Spectroscopy 111,2-diaminocyclohexaneplatinum II citrate 11Radiosurgery 10Everolimus 10tremelimumab 9epacadostat 9Surgical Procedures, Operative 9Sorafenib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Watchful Waiting × Head & Neck × Clear all
NCT02882282 2025-10-23

Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia

M.D. Anderson Cancer Center

Phase 2 Completed
15 enrolled 8 charts
Head & Neck

Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡